PALO ALTO, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- PALO ALTO, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- 180 Life…
Study to explore role of the Company’s anti-NRP2 antibodies in glioblastoma multiforme (GBM), the most common type of primary brain…
Open-label Phase 2 trial in breast cancer to begin this quarter Initial data expected mid-2025 HANOVER, Md., July 30, 2024…
SOL-R evaluates repeat AXPAXLI™ dosing for wet age-related macular degeneration (wet AMD) Global non-inferiority study comparing AXPAXLI, dosed every six…
The collaboration aims to identify and develop accessible, minimally invasive blood-based biomarkers specific for tau pathology in the brainThese tools…
NTLA-3001 is a potential one-time gene editing treatment that may normalize AAT protein levels and halt the progression of lung…
Program Augments Existing Patient Advocacy and Professional Society Donationsto Non-Profit Organizations Aligned with Corporate Values Deadline for Applications is September…
Achieved $8.2 million in OJEMDATM (tovorafenib) net product revenues in initial 2 months of launch Expanded pipeline with DAY301, potential…
ANAVEX®2-73 corrects directly to humans’ translatable EEG biomarkers in a model of Fragile X Syndrome (FXS) Therapeutic potential to address…
JENA, Germany, July 30, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today…